

Applicants: Daniel G. Ericson et al. Examiner: Patricia Bianco

Serial No.: 10/806,795 Group Art Unit: 3761

Filing Date: March 23, 2004 Docket No.: P-9006.04

Title: HEMOSTATIC SYSTEM AND COMPONENTS FOR EXTRACORPOREAL CIRCUIT

<u>CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8</u>: I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this April, 2006.

Signature

Jo L. Brecht

Printed Name

TERMINAL DISCLAIMER UNDER 37 C.F.R. § 1.321(b)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Certificate Under 37 C.F.R. § 3.73(b)

Your petitioner, Medtronic, Inc., a corporation of the State of Minnesota having a place of business at 710 Medtronic Parkway, Minneapolis, Minnesota, certifies that it is the exclusive owner of the entire right, title and interest in and to the above-identified patent application (Serial No 10/806,795) and in and to U.S. Patent application Serial No. 09/662,044. U.S. Patent application Serial No. 09/662,044 is now U.S. Patent No. 6,733,471.

Your petitioner owns the entire right, title and interest in and to these applications by nature of the assignments executed and filed for U.S. Patent Application Serial No. 09/662,044. The assignment for U.S. Patent application Serial No. 09/662,044 was recorded on January 17, 2003 at Reel 013693, Frames 0722-0724, 737-739 and 742-744, with the United States Patent and Trademark Office. U.S. Patent application Serial No 10/806,795 is a continuation application of U.S. Patent application Serial No. 09/662,044.

Dkt.: P-9006.04

Serial No. 10/806,795

Filing Date: March 23, 2004

Title: HEMOSTATIC SYSTEM AND COMPONENTS FOR EXTRACORPOREAL CIRCUIT

The undersigned (whose title is supplied below) is empowered to act on behalf of Petitioner.

Documents establishing the chain of title of the subject patent application (including the aforementioned assignment and a notice from the Patent and Trademark Office noting its recording location) have been reviewed and I certify that, to the best of my knowledge and belief, title is in Petitioner.

Terminal Disclaimer

Petitioner hereby disclaims, except as provided below, the terminal part of any patent granted on the above-identified patent application that would extend beyond the expiration date of a full statutory term as defined in 35 U.S.C. §154 to §156 and §173 of U.S. Patent No. 6,733,471, not shortened by terminal disclaimer. Petitioner hereby agrees that any patent granted on the above-identified patent application shall be enforceable only for and during such period that the legal title to such patent and U.S. Patent No. 6,733,471 are commonly owned. This agreement is to run with any patent granted on the above-identified patent application and to be binding upon the grantee, its successors and assigns.

Limitations on the Disclaimer

In making the above disclaimer, Petitioner does not disclaim any terminal part of any patent granted on the above-identified patent application prior to the expiration date of the full statutory term, not shortened by terminal disclaimer, of U.S. Patent No. 6,733,471, if such patent: (1) expires for failure to pay a maintenance fee; (2) is held unenforceable or is found invalid by a court of competent jurisdiction; (3) is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321; (4) has all claims canceled by a reexamination certificate; (5) is reissued; or (6) is otherwise terminated prior to the expiration of its full statutory term.

Serial No. 10/806,795 Dkt.: P-9006.04

Filing Date: March 23, 2004

Title: HEMOSTATIC SYSTEM AND COMPONENTS FOR EXTRACORPOREAL CIRCUIT

I hereby declare that all statements made herein of my own knowledge are true and that all statements made herein on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the above-identified application or any patent issuing thereon.

Please charge \$130.00 to Deposit Account No. 13-2546 for the fee required by 37 C.F.R. § 1.20(d). Please charge any additional required fees or credit any overpayment to Deposit Account No. 13-2546.

Respectfully submitted,

Date: April 17 , 2006

Earle F. Kyle, IV

Vice President, Senior Counsel

Medtronic, Inc.

7601 Northland Drive Minneapolis, MN 55428

Telephone: (763) 391-9280

Fax. (763) 391-9668